Abstract | PURPOSE OF REVIEW: The identification of the JAK2V617F allele greatly improved our understanding of the molecular pathogenesis of myeloproliferative disorders. This review focuses on recent studies offering new genetic, biochemical, and functional insight into the role of JAK2V617F in the pathogenesis of these disorders. RECENT FINDINGS: SUMMARY: The discovery of the JAK2V617F allele represents an important advance in our understanding of the molecular pathogenesis of myeloproliferative disorders, though many questions remain regarding the role of a single allele in three clinically distinct disorders, the mechanism of activation of JAK2V617F, and the pathogenesis of JAK2-negative myeloproliferative disorders.
|
Authors | Ross L Levine, D Gary Gilliland |
Journal | Current opinion in hematology
(Curr Opin Hematol)
Vol. 14
Issue 1
Pg. 43-7
(Jan 2007)
ISSN: 1065-6251 [Print] United States |
PMID | 17133099
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Receptors, Thrombopoietin
- MPL protein, human
- Janus Kinase 2
|
Topics |
- Humans
- Janus Kinase 2
(genetics)
- Myeloproliferative Disorders
(genetics, physiopathology)
- Point Mutation
(genetics, physiology)
- Receptors, Thrombopoietin
(genetics)
- Signal Transduction
(physiology)
|